{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:35:06Z","timestamp":1785900906821,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22101001"],"award-info":[{"award-number":["22101001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91961121"],"award-info":[{"award-number":["91961121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21631001"],"award-info":[{"award-number":["21631001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22003054"],"award-info":[{"award-number":["22003054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21871001"],"award-info":[{"award-number":["21871001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115855","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T18:46:29Z","timestamp":1697049989000},"page":"115855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice"],"prefix":"10.1016","volume":"261","author":[{"given":"Yonglei","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3068-7160","authenticated-orcid":false,"given":"Manzhou","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115855_bib1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(16)31140-0","article-title":"Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial","volume":"388","author":"Richards","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115855_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003215","article-title":"Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: a population-based cohort study","volume":"17","author":"Jack","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2023.115855_bib3","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05343-3","article-title":"Non-canonical \u03b2-adrenergic activation of ERK at endosomes","volume":"611","author":"Kwon","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115855_bib5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejmech.2017.03.071","article-title":"Discovery of 4-amino-3-arylsulfoquinolines, a novel non-acetylenic chemotype of metabotropic glutamate 5 (mGlu5) receptor negative allosteric modulators","volume":"133","author":"Galambos","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ejmech.2017.01.013","article-title":"Positional isomers of bispyridine benzene derivatives induce efficacy changes on mGlu5 negative allosteric modulation","volume":"127","author":"G\u00f3mez-Santacana","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature13396","article-title":"Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain","volume":"511","author":"Dor\u00e9","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115855_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cell.2009.12.055","article-title":"DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke","volume":"140","author":"Tu","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115855_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2016.0838","article-title":"Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial","volume":"73","author":"Quiroz","year":"2016","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.ejmech.2023.115855_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/cn100099n","article-title":"(3-cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): discovery of a new tool compound with activity in the OSS mouse model of addiction","volume":"2","author":"Lindsley","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115855_bib11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acs.jmedchem.8b01226","article-title":"Evaluation of amides, carbamates, sulfonamides, and ureas of 4-prop-2-ynylidenecycloalkylamine as potent, selective, and bioavailable negative allosteric modulators of metabotropic glutamate receptor 5","volume":"62","author":"Graziani","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib12","doi-asserted-by":"crossref","first-page":"64ra1","DOI":"10.1126\/scitranslmed.3001708","article-title":"Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056","volume":"3","author":"Jacquemont","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2023.115855_bib13","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1021\/jm501642c","article-title":"Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazole-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases","volume":"58","author":"Jaeschke","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0028-3908(99)00082-9","article-title":"2-methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist","volume":"38","author":"Gasparini","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115855_bib15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/13543776.2017.1280466","article-title":"mGlu5 negative allosteric modulators: a patent review (2013 - 2016)","volume":"27","author":"Emmitte","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115855_bib16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2a trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2023.115855_bib17","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/cells12071004","article-title":"Effect of the metabotropic glutamate receptor type 5 negative allosteric modulator dipraglurant on motor and non-motor symptoms of Parkinson's disease","volume":"12","author":"Epping-Jordan","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.115855_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.114.222463","article-title":"Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression","volume":"353","author":"Lindemann","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115855_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/jm025570j","article-title":"3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity","volume":"46","author":"Cosford","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/acs.jmedchem.7b01722","article-title":"Structure-based optimization strategies for G protein-coupled receptor (GPCR) allosteric modulators: a case study from analyses of new metabotropic glutamate receptor 5 (mglu5) x-ray structures","volume":"62","author":"Christopher","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib21","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1021\/acs.jmedchem.6b01858","article-title":"Discovery and preclinical characterization of 3-((4-(4-chlorophenyl)-7-fluoroquinoline-3-yl) sulfonyl) benzonitrile, a novel non-acetylenic metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator for psychiatric indications","volume":"60","author":"Galambos","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/j.pain.0000000000001695","article-title":"The metabotropic glutamate receptor 5 negative allosteric modulator fenobam: pharmacokinetics, side effects, and analgesic effects in healthy human subjects","volume":"161","author":"Cavallone","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2023.115855_bib23","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1021\/acs.jmedchem.5b00892","article-title":"Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)","volume":"58","author":"Christopher","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib24","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1021\/acs.jmedchem.7b00410","article-title":"Discovery of N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5 selected for clinical evaluation","volume":"60","author":"Felts","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib25","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/cn400070k","article-title":"Substituted 1-phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction","volume":"4","author":"Amato","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115855_bib26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/jm401622k","volume":"57","author":"Zhang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib27","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.1021\/acs.jmedchem.7b00604","volume":"60","author":"Stepan","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib28","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.chembiol.2017.06.003","article-title":"Mechanisms of skin toxicity associated with metabotropic glutamate receptor 5 negative allosteric modulators","volume":"24","author":"Shah","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115855_bib29","article-title":"Preparation of pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists","volume":"164","author":"Gideon","year":"2016","journal-title":"Chem. Abstr."},{"key":"10.1016\/j.ejmech.2023.115855_bib30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.22159\/ajpcr.2017.v10i11.21773","article-title":"Antidepressant activity of thymoquinone possibly through involvement of corticotropin-releasing factor","volume":"10","author":"Jain","year":"2017","journal-title":"Asian J. Pharmaceut. Clin. Res."},{"key":"10.1016\/j.ejmech.2023.115855_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0278-5846(03)00051-4","article-title":"Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice","volume":"27","author":"Ducottet","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2023.115855_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.119.119032","article-title":"Detailed in vitro pharmacological characterization of clinically tested negative allosteric modulators of the metabotropic glutamate receptor 5","volume":"98","author":"Arsova","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115855_bib33","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.pharep.2019.07.011","article-title":"Coumarin and 3,4-dihydroquinolinone derivatives: synthesis, antidepressant activity, and molecular docking studies","volume":"71","author":"Wang","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2023.115855_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/1039856218794874","article-title":"Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant","volume":"26","author":"Keks","year":"2018","journal-title":"Australas. Psychiatr."},{"key":"10.1016\/j.ejmech.2023.115855_bib35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cmet.2022.03.006","article-title":"Identification and evaluation of a lipid-lowering small compound in preclinical models and in a phase I trial","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2023.115855_bib36","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1021\/acs.jmedchem.2c00040","article-title":"Novel sphingosine kinase 1 inhibitor suppresses growth of solid tumor and inhibits the lung metastasis of triple-negative breast cancer","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115855_bib37","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.apsb.2019.06.006","article-title":"Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin\/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia","author":"Wu","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115855_bib38","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1021\/acs.jmedchem.5b02023","article-title":"Design, synthesis, and biological evaluation of indoline and indole derivatives as potent and selective \u03b11A-adrenoceptor antagonists","volume":"59","author":"Zhao","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib39","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.bmc.2016.03.061","article-title":"Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2","volume":"24","author":"Qiang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.105.089839","article-title":"Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity","volume":"315","author":"Porter","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115855_bib41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.apsb.2015.01.008","article-title":"Synthesis, potential anticonvulsant and antidepressant effects of 2-(5-methyl-2,3-dioxoindolin-1-yl)acetamide derivatives","volume":"5","author":"Zhen","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115855_bib42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jep.2009.05.001","article-title":"Antidepressant-like effect of Lafoensia pacari A. St.-Hil. ethanolic extract and fractions in mice","volume":"124","author":"Galdino","year":"2009","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2023.115855_bib43","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1248\/bpb.29.1767","article-title":"Antidepressant effect of extracts from Ginkgo biloba leaves in behavioral models","volume":"29","author":"Sakakibara","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2023.115855_bib44","article-title":"Chronic stress-induced gene changes in vitro and in vivo: potential biomarkers associated with depression and cancer based on circRNA- and lncRNA-associated ceRNA networks","volume":"11","author":"Zhou","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2023.115855_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113030","article-title":"cAMP-PKA cascade: an outdated topic for depression?","volume":"150","author":"Gao","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115855_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.jafc.1c06475","article-title":"Sea cucumber peptides attenuated the scopolamine-induced memory impairment in mice and rats and the underlying mechanism","volume":"70","author":"Lu","year":"2022","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2023.115855_bib47","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1523\/JNEUROSCI.3148-16.2017","article-title":"Ubiquitin C-terminal hydrolase L1 (UCH-L1) promotes hippocampus-dependent memory via its deubiquitinating effect on TrkB","volume":"37","author":"Guo","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115855_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.47","article-title":"Serum BDNF levels before and after the development of mood disorders: a case-control study in a population cohort","volume":"6","author":"Ihara","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejmech.2023.115855_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108708","article-title":"GluA1-homomeric AMPA receptor in synaptic plasticity and neurological diseases","volume":"197","author":"Ge","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115855_bib50","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.neurom.2021.09.003","article-title":"Synaptic plasticity 101: the story of the AMPA receptor for the brain stimulation practitioner","volume":"25","author":"Brown","year":"2022","journal-title":"Neuromodulation"},{"key":"10.1016\/j.ejmech.2023.115855_bib51","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.drudis.2021.07.027","article-title":"Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: a long and winding road","volume":"26","author":"Kadriu","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115855_bib52","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.3390\/ijms19113697","article-title":"Medium-chain triglycerides attenuate liver injury in lipopolysaccharide-challenged pigs by inhibiting necroptotic and inflammatory signaling pathways","volume":"19","author":"Zhang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115855_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023540","article-title":"Panax notoginseng saponin protects against diabetic cardiomyopathy through lipid metabolism modulation","volume":"11","author":"Zhang","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejmech.2023.115855_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114164","article-title":"Polygonatum sibiricum polysaccharide prevents depression-like behaviors by reducing oxidative stress, inflammation, and cellular and synaptic damage","volume":"275","author":"Shen","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2023.115855_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108175","article-title":"Calpain inhibition ameliorates depression-like behaviors by reducing inflammation and promoting synaptic protein expression in the hippocampus","volume":"174","author":"Song","year":"2020","journal-title":"Neuropharmacology"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300822X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300822X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:04:22Z","timestamp":1777529062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342300822X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"alternative-id":["S022352342300822X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115855","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115855"}}